Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST)
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, tolerability of imatinib in the neoadjuvant
treatment (pre-operatory) of patients with GIST. It will also evaluate the potential of
imatinib to convert a tumor from inoperable to operable.